Advertisement
Advertisement
U.S. markets open in 7 hours 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Santhera Pharmaceuticals Holding AG (SPHDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.40000.0000 (0.00%)
At close: 10:01AM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4000
Open1.4000
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4000 - 1.4000
52 Week Range1.3700 - 5.6100
Volume3,448
Avg. Volume932
Market Cap24.534M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-3.2190
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for SPHDF

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • SANTHERA PHARMACEUTICALS HOLDIN
    Weekly Stock ListESG (Environmental, Social, Governance) investing continues to grow. According to Opimas, a management consultancy focused on global capital markets, global assets under management in ESG strategies had grown to $40.5 trillion in 2020, doubling in four years and tripling in eight years. As assets have flowed in over the past 40 years, Sustainable Impact Investing has evolved. The discipline, originally known as Socially Responsible Investing, focused at first on excluding companies that conducted business in South Africa, or participated in industries such as tobacco, alcohol and firearms. In time, the list of industries to avoid increased to include soft drinks, fast food, and oil and gas, among numerous others. Performance of these initial strategies lagged, and the approach has been modified. Now, instead of merely identifying industries to avoid, the discipline promotes "sustainable" business practices across all industries that can have an "impact" on global issues such as the climate, hunger, poverty, disease, shelter, and workers' rights. For our part, we track ESG developments at specific companies as part of our Management analysis - one of the six points in our proprietary Six-Point Fundamental Approach. In addition to following the ESG proclamations from the companies under coverage, we partner with an ESG research firm, the JUST Capital Foundation, and leverage its analysis and insights as well. JUST Capital's mission is to drive measurable corporate change to create a stakeholder-centric, inclusive form of capitalism that reflects the priorities of the American public. JUST utilizes a combination of data-driven research and strategic engagement in an attempt to shift norms and practices in corporate America and the financial markets. Environment, and Shareholders. JUST ESG Custom Ratings rank stocks in the Russell 1000 on these criteria using a scale of 1-100. Drawing on the JUST Capital rankings, we have compiled focused lists of companies followed by Argus Research that are in position to have this type of "sustainable impact" on the environment, workplace, community, and marketplace. These firms have exemplary records not only in delivering on the bottom line, but also in improving the environment, contributing to community relations, and showing respect for their employees. We have lists focused on the top companies in each sector, as well as lists of companies that score well on certain financial metrics, such as yield, beta, value, and momentum. We also have a Theme Model Portfolio based in part on the ESG criteria. To build the Argus U.S. ESG Model Portfolio, we applied financial concepts such as industry diversification, income generation, risk reduction and growth at a reasonable price to our various lists. In addition, all stocks must be on the Argus BUY list. Here are the new stocks that have been added to the Argus U.S. ESG Model Portfolio.
    Rating
    Fair Value
    Economic Moat
    20 hours agoArgus Research
View more
  • GlobeNewswire

    Santhera Provides Corporate Update and Calls Extraordinary General Meeting to Seek Approval for Further Financings

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, November 24, 2021 – Santhera Pharmaceuticals (SIX: SANN) provides an update on its activities and is calling an Extraordinary General Meeting (EGM), which will be held on December 15, 2021, at 10:30 hrs at the domicile of the Company. At the EGM, Santhera seeks authorization for additional funding to enable continued pipeline development and preparations for the commercialization of vamorolone. Corporate Update In the course of th

  • GlobeNewswire

    Santhera and ReveraGen Announce Positive Topline Results with Vamorolone after Completion of the VISION-DMD Study

    Ad hoc announcement pursuant to Art. 53 LR Vamorolone given throughout the study showed sustained efficacy across multiple endpoints over 48 weeks and the good safety and tolerability profile was confirmedSwitching from prednisone to vamorolone after week 24 maintained efficacy and improved on multiple safety parameters including restoration of growth trajectory and reduction of behavioral changes up to week 48Switching from placebo to vamorolone after week 24 resulted in an improvement of multi

  • GlobeNewswire

    Santhera and ReveraGen Announce Successful FDA Pre-NDA Meeting for Vamorolone in Duchenne Muscular Dystrophy

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, and Rockville, MD, USA, November 17, 2021 –Santhera Pharmaceuticals (SIX: SANN) and ReveraGen Biopharma (US: private) announce the successful completion of a first pre-NDA meeting with the U.S. Food and Drug Administration (FDA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The FDA considered both the proposed clinical efficacy and safety data sufficient for an NDA filing. Based on the Fast Track Designati

Advertisement
Advertisement